港股異動 | 創維集團(0751.HK)急漲超7% 本月23日將發佈新一代S系列旗艦新品
格隆匯9月14日丨創維集團(0751.HK)快速拉昇漲超7%,現報2.62港元,成交額放大至7201萬港元,總市值超70億港元。9月23日,創維將在2021秋季新品發佈會上發佈新一代S系列旗艦新品,創維S系列將打造行業新標杆。在今年1月至7月,創維集團出口東盟國家同比增長57%,出口“一帶一路”沿線國家和地區同比增長94%。業內人士稱,近年創維集團在硬科技領域開啟“升維”之路,駛入成長快車道,是非常具有代表性的硬科技龍頭。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.